They have cash for one phase 3, but perhaps not for the second phase 3 and marketing without a partnership. Perhaps a partnership is based on milestones that have not been met yet due to patients living longer in the current phase 3 trial and they need to start funding the other activities soon, as they are having good results so far.
Selling because a company needs additional funds to add shareholder value doesn't seem prudent to me.
News 
Market Data 
Discover 
